Aktaş Elif, Ogedey Esra Deniz, Külah Canan, Beğendik Cömert Füsun
Zonguldak Karaelmas Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Zonguldak, Türkiye.
Mikrobiyol Bul. 2010 Oct;44(4):647-50.
Hepatitis C virus (HCV) is one of the significant causes of hepatitis, cirrhosis and hepatocellular carcinoma all throughout the world. There are six genotypes and more than 50 subtypes of HCV. HCV genotyping is of crucial importance in the determination of the treatment protocols and the follow-up of the clinical course since treatment success is low and the duration of treatment is longer in HCV genotype 1 infected cases. The aim of the present study was to evaluate the HCV genotype profiles of the patients with chronic hepatitis C in Zonguldak, providing the first data about HCV genotypes from western Black-Sea region, Turkey. The HCV genotypes of 44 patients (26 female, 18 male; age range: 29-89 years, mean age: 60.05 ± 10.81 years) with positive anti-HCV antibody and HCV-RNA results, admitted to the hospital between May 2007 and July 2009, were retrospectively evaluated and included in the study. Alanine aminotransferase (ALT) levels of the patients were between 8-160 IU/L (mean 63.99 ± 37.15 IU/L) and the aspartate aminotransferase (AST) levels were between 17-160 IU/L (mean 62.77 ± 36.75 IU/L). HCV antibody was determined by ELISA method (Abbott Laboratories, USA), and HCV-RNA was determined by two commercial real-time polymerase chain reaction systems [Cobas Taqman (Roche Diagnostic, USA) and Rotor-Gene 6000 (Corbett Research, USA)]. The genotyping was performed by a reverse hybridization based method, Versant® HCV Genotype Assay (LiPA) 2.0 (Bayer Health Care, Belgium). HCV genotypes could not be determined for 5 (11.4%) patients since HCV-RNA levels were low. Genotyping could be performed for 39 (88.6%) patients and 38 (97.4%) had genotype 1b and one (2.6%) patient had genotype 1a. In conclusion, in concordance with the other studies conducted in our country, genotype 1b was found to be the most prevalent genotype in patients from our region.
丙型肝炎病毒（HCV）是全球范围内导致肝炎、肝硬化和肝细胞癌的重要病因之一。HCV有六种基因型及50多种亚型。HCV基因分型对于确定治疗方案和临床病程的随访至关重要，因为在感染HCV基因型1的病例中治疗成功率较低且治疗时间较长。本研究的目的是评估宗古尔达克慢性丙型肝炎患者的HCV基因型谱，提供来自土耳其黑海西部地区关于HCV基因型的首批数据。对2007年5月至2009年7月间入院的44例抗-HCV抗体和HCV-RNA结果呈阳性的患者（26例女性，18例男性；年龄范围：29 - 89岁，平均年龄：60.05 ± 10.81岁）的HCV基因型进行回顾性评估并纳入研究。患者的丙氨酸转氨酶（ALT）水平在8 - 160 IU/L之间（平均63.99 ± 37.15 IU/L），天冬氨酸转氨酶（AST）水平在17 - 160 IU/L之间（平均62.77 ± 36.75 IU/L）。HCV抗体通过ELISA方法（美国雅培实验室）测定，HCV-RNA通过两种商业实时聚合酶链反应系统[Cobas Taqman（美国罗氏诊断）和Rotor-Gene 6000（美国Corbett Research）]测定。基因分型采用基于反向杂交的方法，即Versant® HCV基因型检测（LiPA）2.0（比利时拜耳医疗保健公司）。5例（11.4%）患者因HCV-RNA水平低而无法确定HCV基因型。39例（88.6%）患者能够进行基因分型，其中38例（97.4%）为基因型1b，1例（2.6%）患者为基因型1a。总之，与我国进行的其他研究一致，发现基因型1b是我们地区患者中最常见的基因型。
